New York, Feb. 22, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Respiratory Inhalers Industry” – https://www.reportlinker.com/p06032771/?utm_source=GNW
-Online interactive peer-to-peer collaborative bespoke updates
-Access to our digital archives and MarketGlass Research Platform
-Complimentary updates for one year

Global Respiratory Inhalers Market to Reach $48.7 Billion by 2026

Respiratory care market occupies a significant presence in the medical field, as respiratory dysfunction is among the most widespread healthcare problem globally. Growth drivers include increasing incidence of certain respiratory diseases, such as COPD and asthma, significant increase in the number of elderly patients (most of who suffer from at least one type of respiratory ailment), growing knowledge of certain respiratory problems such as obstructive sleep apnea, and the general growth in demand for improved patient care. Respiratory Inhalers have often proven to be life-savers for millions of patients. The main patient segments using inhalers are those suffering from asthma, COPD, and pulmonary arterial hypertension. The surging geriatric population is also using inhalers as they suffer reduced immunity to chronic and pulmonary diseases. Respiratory inhalers are equipped with complementary spacers or holding chamber devices so that there is reduced deposition in the mouth and throat. There is increasing use of respiratory inhalers to treat COPD (Chronic Obstructive Pulmonary Disease) patients and asthma. Combined therapy is more popularly considered as it has shown reliability in complex patients and better efficacy.

Amid the COVID-19 crisis, the global market for Respiratory Inhalers estimated at US$33.9 Billion in the year 2020, is projected to reach a revised size of US$48.7 Billion by 2026, growing at a CAGR of 6% over the analysis period. Manual Inhalers, one of the segments analyzed in the report, is projected to grow at a 5.4% CAGR to reach US$45.4 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Digital Inhalers segment is readjusted to a revised 13.1% CAGR for the next 7-year period. This segment currently accounts for a 6.9% share of the global Respiratory Inhalers market.

The U.S. Market is Estimated at $13.2 Billion in 2021, While China is Forecast to Reach $6.6 Billion by 2026

The Respiratory Inhalers market in the U.S. is estimated at US$13.2 Billion in the year 2021. The country currently accounts for a 36.11% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$6.6 Billion in the year 2026 trailing a CAGR of 8.2% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.1% and 5.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR while Rest of European market (as defined in the study) will reach US$7 Billion by the close of the analysis period. Growth in these regional markets is expected to be driven by the rise of smart inhalers. With newer smart inhaler technology, patients can monitor their doses. Some variants of smart inhalers can measure environmental pollution and alert the patients accordingly about asthma triggers in the air. Few smart inhalers also come with Bluetooth transmitter to connect with the smartphone. Thus, the patient`s frequency of asthma attacks, triggers, and causes can be monitored by the healthcare professional. But it is not easy to train patients in the correct use of nebulizers and inhalers.

Digital Inhalers Segment to Reach $4.9 Billion by 2026

Interactive digital inhalers featuring sophisticated sensors and Artificial Intelligence (AI) technology are being rolled out to assist users to manage the illness by way of guided instructions and recording data pertaining to usage. The combination of conventional digital inhalers and AI-enabled machine learning algorithms ensures patients receive timed instructions and audio-visual cues to use the inhaler appropriately and to take the prescribed medication regularly in order to avoid asthma attacks. AI-enabled drug delivery mechanism holds immense potential in treatment of COPD and other pulmonary ailments in addition to asthma. Global market for Digital Inhalers is estimated at US$2.3 Billion in 2020, and is projected to reach US$4.9 Billion by 2026 reflecting a compounded annual growth rate of 13.1% over the analysis period. United States constitutes the largest regional market for Digital segment, accounting for 42.5% of the global sales in 2020. China is poised to register the fastest compounded annual growth rate of 16.4% over the analysis period, to reach US$480.1 Million by the end of the analysis period.
Select Competitors (Total 131 Featured) –

• Adherium Limited
• AstraZeneca plc
• Beximco Pharmaceuticals Ltd.
• Boehringer Ingelheim International GmbH
• CHIESI Farmaceutici S.p.A.
• Cipla Inc.
• GlaxoSmithKline plc
• Glenmark Pharmaceuticals Ltd.
• HELTMAN Medikal A.S.
• Koninklijke Philips N.V.
• Merck & Co., Inc.
• Mundipharma International Limited
• Novartis International AG
• Omron Healthcare, Inc.
• PARI GmbH
• Teva Pharmaceutical Industries Ltd.

Read the full report: https://www.reportlinker.com/p06032771/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
2020 Marked as a Year of Disruption & Transformation
World Economic Growth Projections (Real GDP, Annual % Change)
for 2019 to 2022
Inhalation Technology for Tackling COVID-19s
Iconovo Joins Hands with ISR to Develop Inhaled Vaccine for
COVID-19
Ongoing Studies ExploreUse of Inhalers-based Therapies to Treat
COVID-19
Inhalers Lead to Marked Reduction in Onset of Severe Symptoms
for Early COVID-19 Patients
Researchers Bet on Corticosteroid Inhalers to Treat COVID-19
Patients
Use of Inhalers amid COVID-19 Medical Crisis Outweigh Risks for
Asthma Patients
COVID-19 Pandemic Pushes Patient Compliance Linked with
Inhaler-based Drug Regime
Stockpiling Under COVID-19 Shadow Exacerbates Steroid Inhaler
Supply Concerns
Concerns over COVID-19 Virus Transmission through Nebulizers
Paves Way for Broader Acceptance of Respiratory Inhalers
Respiratory Inhalers – Global Key Competitors Percentage Market
Share in 2022 (E)
Competitive Market Presence – Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
Respiratory Inhalers: A Prelude
Types of Respiratory Inhalers
Metered-dose inhaler
Dry Powder Inhaler (DPI)
Soft Mist Inhalers (SMI)
Nebulizers
Pulmonary Drug Delivery using Inhalers Hold Critical
Significance to Provide Respite to Patients
High Prevalence of Respiratory Diseases to Drive Growth
Prevalence Percentage of COPD, Asthma, and Allergic Rhinitis
for Select Countries: 2016
EXHIBIT 2:Chronic Disease Management in Developed Countries:
(2019): Percentage Distribution of Patient Population by
Chronic Disease Type in the US, Germany, and UK
Sustained Emphasis on Bringing Novel Pulmonary Disease
Treatments Augurs Well for Market Growth
Dry Powder Inhalers Set to Drive Gains
Digital Dose Inhalers Accelerate Growth Pace
Global Cost of Respiratory Therapy by Disease (2019):
Percentage Breakdown of Therapy Costs for Asthma, Chronic
Obstructive Pulmonary Disease (COPD), Idiopathic Pulmonary
Fibrosis, and Others
Recent Market Activity

2. FOCUS ON SELECT PLAYERS
Growing Homecare Market Drives Demand for Respiratory
Diagnostic and Therapy Devices

3. MARKET TRENDS & DRIVERS
Rise in Incidence of Asthma Drives Growth Prospects
Role of Respiratory Inhalers in Asthma
Asthma Rescue Inhalers Medications
Asthma Long-Term Medications
Select Asthma Stats
Asthma Prevalence in the US by Age: 2019
Asthma Prevalence in the US by Gender: 2019
Asthma Prevalence in the US by Race/Ethnicity: 2019
Rising Prevalence of Asthma in Children Supports Growth
Mounting Incidence of COPD Drives Use of Inhalers
COPD Stats
Global Prevalence of COPD by Age Group: Percentage of Men and
Women Affected by the Condition
Reported COPD Cases in the US in Million : 2014-2018
Acute Respiratory Distress Syndrome: An Emerging Space for
Inhalers
ARDS Fact Sheet
Rising Incidence of Cystic Fibrosis Offers Market Potential
Global Frequency of Genetic Mutations Carrying Cystic Fibrosis
Cystic Fibrosis Fact Sheet
Combination Therapies Gain Interest as Effective Treatment for
Considered Influence Respiratory Inhaler Demand
Nebulizer Innovations Drive Opportunities
Global Nebulizer Devices Market by Type: 2020
Manufacturers Venture into Nebulizers Designed to Fight COVID-19
New Hot Melt Extrusion Method to Enhance Inhaler Technology
Advances in Pulmonary Drug Delivery Devices Drive Adoption
Select Innovations & Advancements
Smart Inhalers Gain Traction
Artificial Intelligence to Add Sophistication to Inhaler
Technology
3D Printing Seeks Role in Inhaler Manufacturing
Rise in Air Pollution Levels and Consequent Increase in
Respiratory Diseases Trigger the Demand for Inhalers
Global Indoor Air Pollution Related Fatalities by Health
Condition (In %) for 2020E
Air Pollution Levels Worldwide: Average PM2.5 Concentration
(in µg/m³) in Select Countries for 2019
Global Carbon Dioxide (CO2) Emissions (in Billion Metric Tons):
2010-2019
Countries with Highest Carbon Emissions Worldwide: Percentage
Breakdown of Carbon Emissions by Country (in %) for 2020E
Inhalers and Pollution: The Irony
Ballooning Geriatric Population to Spur Demand
Global Aging Population Statistics for the 65+ Age Group in
Million by Geographic Region for the Years 2019, 2025, 2035
and 2050
Table 5: Global Life Expectancy at Age 60 and 80 Years: 2010-
2015; 2020-2025; and 2045-2050
Increase in Healthcare Spending Stirs Demand
World Healthcare Expenditure (In US$ Billion) for the Years
2017-2023

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Manual by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Manual by Geographic Region –
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 3: World 15-Year Perspective for Manual by Geographic
Region – Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 4: World Recent Past, Current & Future Analysis for
Digital by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Digital by Geographic Region –
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 6: World 15-Year Perspective for Digital by Geographic
Region – Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 7: World Recent Past, Current & Future Analysis for
Metered Dose by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Metered Dose by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 9: World 15-Year Perspective for Metered Dose by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 10: World Recent Past, Current & Future Analysis for Dry
Powder by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for Dry Powder by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 12: World 15-Year Perspective for Dry Powder by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 13: World Recent Past, Current & Future Analysis for
Nebulizers by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Nebulizers by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 15: World 15-Year Perspective for Nebulizers by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 16: World Recent Past, Current & Future Analysis for
Asthma by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Asthma by Geographic Region –
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 18: World 15-Year Perspective for Asthma by Geographic
Region – Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 19: World Recent Past, Current & Future Analysis for COPD
by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 20: World Historic Review for COPD by Geographic Region –
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets – Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for COPD by Geographic
Region – Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 22: World Recent Past, Current & Future Analysis for
Other Applications by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets – Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 23: World Historic Review for Other Applications by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Other Applications by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 25: World Recent Past, Current & Future Analysis for
Respiratory Inhalers by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets – Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 26: World Historic Review for Respiratory Inhalers by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Respiratory Inhalers by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2012, 2021 & 2027

III. MARKET ANALYSIS

UNITED STATES
Respiratory Inhalers Market Presence – Strong/Active/Niche/
Trivial – Key Competitors in the United States for 2022 (E)
Table 28: USA Recent Past, Current & Future Analysis for
Respiratory Inhalers by Technology – Manual and Digital –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 29: USA Historic Review for Respiratory Inhalers by
Technology – Manual and Digital Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 30: USA 15-Year Perspective for Respiratory Inhalers by
Technology – Percentage Breakdown of Value Sales for Manual and
Digital for the Years 2012, 2021 & 2027

Table 31: USA Recent Past, Current & Future Analysis for
Respiratory Inhalers by Product – Metered Dose, Dry Powder and
Nebulizers – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 32: USA Historic Review for Respiratory Inhalers by
Product – Metered Dose, Dry Powder and Nebulizers Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 33: USA 15-Year Perspective for Respiratory Inhalers by
Product – Percentage Breakdown of Value Sales for Metered Dose,
Dry Powder and Nebulizers for the Years 2012, 2021 & 2027

Table 34: USA Recent Past, Current & Future Analysis for
Respiratory Inhalers by Application – Asthma, COPD and Other
Applications – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 35: USA Historic Review for Respiratory Inhalers by
Application – Asthma, COPD and Other Applications Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 36: USA 15-Year Perspective for Respiratory Inhalers by
Application – Percentage Breakdown of Value Sales for Asthma,
COPD and Other Applications for the Years 2012, 2021 & 2027

CANADA
Table 37: Canada Recent Past, Current & Future Analysis for
Respiratory Inhalers by Technology – Manual and Digital –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 38: Canada Historic Review for Respiratory Inhalers by
Technology – Manual and Digital Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 39: Canada 15-Year Perspective for Respiratory Inhalers
by Technology – Percentage Breakdown of Value Sales for Manual
and Digital for the Years 2012, 2021 & 2027

Table 40: Canada Recent Past, Current & Future Analysis for
Respiratory Inhalers by Product – Metered Dose, Dry Powder and
Nebulizers – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 41: Canada Historic Review for Respiratory Inhalers by
Product – Metered Dose, Dry Powder and Nebulizers Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 42: Canada 15-Year Perspective for Respiratory Inhalers
by Product – Percentage Breakdown of Value Sales for Metered
Dose, Dry Powder and Nebulizers for the Years 2012, 2021 & 2027

Table 43: Canada Recent Past, Current & Future Analysis for
Respiratory Inhalers by Application – Asthma, COPD and Other
Applications – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 44: Canada Historic Review for Respiratory Inhalers by
Application – Asthma, COPD and Other Applications Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 45: Canada 15-Year Perspective for Respiratory Inhalers
by Application – Percentage Breakdown of Value Sales for
Asthma, COPD and Other Applications for the Years 2012, 2021 &
2027

JAPAN
Respiratory Inhalers Market Presence – Strong/Active/Niche/
Trivial – Key Competitors in Japan for 2022 (E)
Table 46: Japan Recent Past, Current & Future Analysis for
Respiratory Inhalers by Technology – Manual and Digital –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 47: Japan Historic Review for Respiratory Inhalers by
Technology – Manual and Digital Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 48: Japan 15-Year Perspective for Respiratory Inhalers by
Technology – Percentage Breakdown of Value Sales for Manual and
Digital for the Years 2012, 2021 & 2027

Table 49: Japan Recent Past, Current & Future Analysis for
Respiratory Inhalers by Product – Metered Dose, Dry Powder and
Nebulizers – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 50: Japan Historic Review for Respiratory Inhalers by
Product – Metered Dose, Dry Powder and Nebulizers Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 51: Japan 15-Year Perspective for Respiratory Inhalers by
Product – Percentage Breakdown of Value Sales for Metered Dose,
Dry Powder and Nebulizers for the Years 2012, 2021 & 2027

Table 52: Japan Recent Past, Current & Future Analysis for
Respiratory Inhalers by Application – Asthma, COPD and Other
Applications – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 53: Japan Historic Review for Respiratory Inhalers by
Application – Asthma, COPD and Other Applications Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 54: Japan 15-Year Perspective for Respiratory Inhalers by
Application – Percentage Breakdown of Value Sales for Asthma,
COPD and Other Applications for the Years 2012, 2021 & 2027

CHINA
Respiratory Inhalers Market Presence – Strong/Active/Niche/
Trivial – Key Competitors in China for 2022 (E)
Table 55: China Recent Past, Current & Future Analysis for
Respiratory Inhalers by Technology – Manual and Digital –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 56: China Historic Review for Respiratory Inhalers by
Technology – Manual and Digital Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 57: China 15-Year Perspective for Respiratory Inhalers by
Technology – Percentage Breakdown of Value Sales for Manual and
Digital for the Years 2012, 2021 & 2027

Table 58: China Recent Past, Current & Future Analysis for
Respiratory Inhalers by Product – Metered Dose, Dry Powder and
Nebulizers – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 59: China Historic Review for Respiratory Inhalers by
Product – Metered Dose, Dry Powder and Nebulizers Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 60: China 15-Year Perspective for Respiratory Inhalers by
Product – Percentage Breakdown of Value Sales for Metered Dose,
Dry Powder and Nebulizers for the Years 2012, 2021 & 2027

Table 61: China Recent Past, Current & Future Analysis for
Respiratory Inhalers by Application – Asthma, COPD and Other
Applications – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 62: China Historic Review for Respiratory Inhalers by
Application – Asthma, COPD and Other Applications Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 63: China 15-Year Perspective for Respiratory Inhalers by
Application – Percentage Breakdown of Value Sales for Asthma,
COPD and Other Applications for the Years 2012, 2021 & 2027

EUROPE
Respiratory Inhalers Market Presence – Strong/Active/Niche/
Trivial – Key Competitors in Europe for 2022 (E)
Table 64: Europe Recent Past, Current & Future Analysis for
Respiratory Inhalers by Technology – Manual and Digital –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 65: Europe Historic Review for Respiratory Inhalers by
Technology – Manual and Digital Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 66: Europe 15-Year Perspective for Respiratory Inhalers
by Technology – Percentage Breakdown of Value Sales for Manual
and Digital for the Years 2012, 2021 & 2027

Table 67: Europe Recent Past, Current & Future Analysis for
Respiratory Inhalers by Product – Metered Dose, Dry Powder and
Nebulizers – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 68: Europe Historic Review for Respiratory Inhalers by
Product – Metered Dose, Dry Powder and Nebulizers Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 69: Europe 15-Year Perspective for Respiratory Inhalers
by Product – Percentage Breakdown of Value Sales for Metered
Dose, Dry Powder and Nebulizers for the Years 2012, 2021 & 2027

Table 70: Europe Recent Past, Current & Future Analysis for
Respiratory Inhalers by Application – Asthma, COPD and Other
Applications – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 71: Europe Historic Review for Respiratory Inhalers by
Application – Asthma, COPD and Other Applications Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 72: Europe 15-Year Perspective for Respiratory Inhalers
by Application – Percentage Breakdown of Value Sales for
Asthma, COPD and Other Applications for the Years 2012, 2021 &
2027

Table 73: Europe Recent Past, Current & Future Analysis for
Respiratory Inhalers by Geographic Region – France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 74: Europe Historic Review for Respiratory Inhalers by
Geographic Region – France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets – Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 75: Europe 15-Year Perspective for Respiratory Inhalers
by Geographic Region – Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2012, 2021 & 2027

FRANCE
Respiratory Inhalers Market Presence – Strong/Active/Niche/
Trivial – Key Competitors in France for 2022 (E)
Table 76: France Recent Past, Current & Future Analysis for
Respiratory Inhalers by Technology – Manual and Digital –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 77: France Historic Review for Respiratory Inhalers by
Technology – Manual and Digital Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 78: France 15-Year Perspective for Respiratory Inhalers
by Technology – Percentage Breakdown of Value Sales for Manual
and Digital for the Years 2012, 2021 & 2027

Table 79: France Recent Past, Current & Future Analysis for
Respiratory Inhalers by Product – Metered Dose, Dry Powder and
Nebulizers – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 80: France Historic Review for Respiratory Inhalers by
Product – Metered Dose, Dry Powder and Nebulizers Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 81: France 15-Year Perspective for Respiratory Inhalers
by Product – Percentage Breakdown of Value Sales for Metered
Dose, Dry Powder and Nebulizers for the Years 2012, 2021 & 2027

Table 82: France Recent Past, Current & Future Analysis for
Respiratory Inhalers by Application – Asthma, COPD and Other
Applications – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 83: France Historic Review for Respiratory Inhalers by
Application – Asthma, COPD and Other Applications Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 84: France 15-Year Perspective for Respiratory Inhalers
by Application – Percentage Breakdown of Value Sales for
Asthma, COPD and Other Applications for the Years 2012, 2021 &
2027

GERMANY
Respiratory Inhalers Market Presence – Strong/Active/Niche/
Trivial – Key Competitors in Germany for 2022 (E)
Table 85: Germany Recent Past, Current & Future Analysis for
Respiratory Inhalers by Technology – Manual and Digital –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 86: Germany Historic Review for Respiratory Inhalers by
Technology – Manual and Digital Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 87: Germany 15-Year Perspective for Respiratory Inhalers
by Technology – Percentage Breakdown of Value Sales for Manual
and Digital for the Years 2012, 2021 & 2027

Table 88: Germany Recent Past, Current & Future Analysis for
Respiratory Inhalers by Product – Metered Dose, Dry Powder and
Nebulizers – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 89: Germany Historic Review for Respiratory Inhalers by
Product – Metered Dose, Dry Powder and Nebulizers Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 90: Germany 15-Year Perspective for Respiratory Inhalers
by Product – Percentage Breakdown of Value Sales for Metered
Dose, Dry Powder and Nebulizers for the Years 2012, 2021 & 2027

Table 91: Germany Recent Past, Current & Future Analysis for
Respiratory Inhalers by Application – Asthma, COPD and Other
Applications – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 92: Germany Historic Review for Respiratory Inhalers by
Application – Asthma, COPD and Other Applications Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 93: Germany 15-Year Perspective for Respiratory Inhalers
by Application – Percentage Breakdown of Value Sales for
Asthma, COPD and Other Applications for the Years 2012, 2021 &
2027

ITALY
Table 94: Italy Recent Past, Current & Future Analysis for
Respiratory Inhalers by Technology – Manual and Digital –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 95: Italy Historic Review for Respiratory Inhalers by
Technology – Manual and Digital Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 96: Italy 15-Year Perspective for Respiratory Inhalers by
Technology – Percentage Breakdown of Value Sales for Manual and
Digital for the Years 2012, 2021 & 2027

Table 97: Italy Recent Past, Current & Future Analysis for
Respiratory Inhalers by Product – Metered Dose, Dry Powder and
Nebulizers – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 98: Italy Historic Review for Respiratory Inhalers by
Product – Metered Dose, Dry Powder and Nebulizers Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 99: Italy 15-Year Perspective for Respiratory Inhalers by
Product – Percentage Breakdown of Value Sales for Metered Dose,
Dry Powder and Nebulizers for the Years 2012, 2021 & 2027

Table 100: Italy Recent Past, Current & Future Analysis for
Respiratory Inhalers by Application – Asthma, COPD and Other
Applications – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 101: Italy Historic Review for Respiratory Inhalers by
Application – Asthma, COPD and Other Applications Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 102: Italy 15-Year Perspective for Respiratory Inhalers
by Application – Percentage Breakdown of Value Sales for
Asthma, COPD and Other Applications for the Years 2012, 2021 &
2027

UNITED KINGDOM
Respiratory Inhalers Market Presence – Strong/Active/Niche/
Trivial – Key Competitors in the United Kingdom for 2022 (E)
Table 103: UK Recent Past, Current & Future Analysis for
Respiratory Inhalers by Technology – Manual and Digital –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 104: UK Historic Review for Respiratory Inhalers by
Technology – Manual and Digital Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 105: UK 15-Year Perspective for Respiratory Inhalers by
Technology – Percentage Breakdown of Value Sales for Manual and
Digital for the Years 2012, 2021 & 2027

Table 106: UK Recent Past, Current & Future Analysis for
Respiratory Inhalers by Product – Metered Dose, Dry Powder and
Nebulizers – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 107: UK Historic Review for Respiratory Inhalers by
Product – Metered Dose, Dry Powder and Nebulizers Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 108: UK 15-Year Perspective for Respiratory Inhalers by
Product – Percentage Breakdown of Value Sales for Metered Dose,
Dry Powder and Nebulizers for the Years 2012, 2021 & 2027

Table 109: UK Recent Past, Current & Future Analysis for
Respiratory Inhalers by Application – Asthma, COPD and Other
Applications – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 110: UK Historic Review for Respiratory Inhalers by
Application – Asthma, COPD and Other Applications Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 111: UK 15-Year Perspective for Respiratory Inhalers by
Application – Percentage Breakdown of Value Sales for Asthma,
COPD and Other Applications for the Years 2012, 2021 & 2027

SPAIN
Table 112: Spain Recent Past, Current & Future Analysis for
Respiratory Inhalers by Technology – Manual and Digital –
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 113: Spain Historic Review for Respiratory Inhalers by
Technology – Manual and Digital Markets – Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 114: Spain 15-Year Perspective for Respiratory Inhalers
by Technology – Percentage Breakdown of Value Sales for Manual
and Digital for the Years 2012, 2021 & 2027

Table 115: Spain Recent Past, Current & Future Analysis for
Respiratory Inhalers by Product – Metered Dose, Dry Powder and
Nebulizers – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 116: Spain Historic Review for Respiratory Inhalers by
Product – Metered Dose, Dry Powder and Nebulizers Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 117: Spain 15-Year Perspective for Respiratory Inhalers
by Product – Percentage Breakdown of Value Sales for Metered
Dose, Dry Powder and Nebulizers for the Years 2012, 2021 & 2027

Table 118: Spain Recent Past, Current & Future Analysis for
Respiratory Inhalers by Application – Asthma, COPD and Other
Applications – Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 119: Spain Historic Review for Respiratory Inhalers by
Application – Asthma, COPD and Other Applications Markets –
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 120: Spain 15-Year Perspective for Respiratory Inhalers
by Application – Percentage Breakdown of Value Sales for
Asthma, COPD and Other Applications for the Years 2012, 2021 &
2027

RUSSIA

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06032771/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________